Download PDF
Digestive Disease Interventions
DOI: 10.1055/s-0044-1787960
Review Article

Endoscopic Ablation of Perihilar Biliary Malignancies

Ross C. D. Buerlein 
1   Division of Gastroenterology and Hepatology, University of Virginia Health System, Charlottesville, Virginia
,
Arjun Kundra
1   Division of Gastroenterology and Hepatology, University of Virginia Health System, Charlottesville, Virginia
,
Andrew Y. Wang
1   Division of Gastroenterology and Hepatology, University of Virginia Health System, Charlottesville, Virginia
› Author Affiliations Financial Disclosures R.C.D.B.: no financial disclosures.
A.K.: no financial disclosures.
A.Y.W.: discloses publicly owned stock equity in Pfizer and GE HealthCare Technologies.
› Further Information
Also available at
    Permissions and Reprints

Abstract

Cholangiocarcinoma (CCA) is a malignancy arising from biliary epithelial cells and is subdivided based on the location within the biliary tree. The treatment of CCA differs based on the anatomical involvement within the biliary tree. Perihilar CCA (pCCA) arises between the cystic duct and the secondary branches of the right and left hepatic ducts. Surgical resection and liver transplantation offer the only hope for cure in pCCA, but, unfortunately, more than 80% of patients are considered surgically unresectable at the time of diagnosis resulting in a limited overall life expectancy of less than 1 year. For patients with surgically unresectable pCCA, treatment options are limited and include chemotherapy/chemoradiotherapy and biliary drainage via endoscopic stenting or percutaneous drainage with minimal overall survival benefits. However, endobiliary ablation options like photodynamic therapy (PDT), radiofrequency ablation (RFA), and, to a lesser degree, intraluminal brachytherapy have shown improvements in overall survival and improvements in stent patency and now should be considered for all cases of surgically unresectable pCCA. In fact, the 2023 American College of Gastroenterology (ACG) Clinical Guidelines on the diagnosis and management of biliary strictures recommend endobiliary ablation (PDT or RFA) for patients with surgically unresectable pCCA rather than stenting alone.

Keywords

cholangiocarcinoma - endobiliary ablation - radiofrequency ablation - photodynamic therapy - brachytherapy


Publication History

Received: 07 May 2024

Accepted: 30 May 2024

Article published online:
27 June 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Buerlein RCD, Podboy AJ, Strand DS. Individualized approach to the management of hilar cholangiocarcinoma: how we do it. Am J Gastroenterol 2023; 118 (12) 2101-2105
    CrossrefPubMedGoogle Scholar
  • 2 Buerlein RCD, Wang AY. Endoscopic retrograde cholangiopancreatography-guided ablation for cholangiocarcinoma. Gastrointest Endosc Clin N Am 2019; 29 (02) 351-367
    CrossrefPubMedGoogle Scholar
  • 3 Forner A, Vidili G, Rengo M, Bujanda L, Ponz-Sarvisé M, Lamarca A. Clinical presentation, diagnosis and staging of cholangiocarcinoma. Liver Int 2019; 39 (Suppl. 01) 98-107
    CrossrefPubMedGoogle Scholar
  • 4 Weismüller TJ. Role of intraductal RFA: a novel tool in the palliative care of perihilar cholangiocarcinoma. Visc Med 2021; 37 (01) 39-47
    CrossrefPubMedGoogle Scholar
  • 5 Di Girolamo E, Belli A, Ottaiano A. et al. Impact of endobiliary radiofrequency ablation on survival of patients with unresectable cholangiocarcinoma: a narrative review. Front Oncol 2023; 13: 1077794
    CrossrefPubMedGoogle Scholar
  • 6 Elmunzer BJ, Maranki JL, Gómez V. et al. ACG clinical guideline: diagnosis and management of biliary strictures. Am J Gastroenterol 2023; 118 (03) 405-426
    CrossrefPubMedGoogle Scholar
  • 7 Song S, Jin H, Cheng Q. et al. Local palliative therapies for unresectable malignant biliary obstruction: radiofrequency ablation combined with stent or biliary stent alone? An updated meta-analysis of nineteen trials. Surg Endosc 2022; 36 (08) 5559-5570
    CrossrefPubMedGoogle Scholar
  • 8 Hayat U, Ashfaq MZ, Haseeb M. et al. Adjuvant radiofrequency ablation along with stenting versus stenting alone for biliary tree drainage in patients with malignant biliary strictures: a systemic review and meta-analysis. J Clin Gastroenterol 2024; 58 (03) 297-306
    CrossrefPubMedGoogle Scholar
  • 9 de Oliveira Veras M, de Moura DTH, McCarty TR. et al. Intraductal radiofrequency ablation plus biliary stent versus stent alone for malignant biliary obstruction: a systematic review and meta-analysis. Endosc Int Open 2024; 12 (01) E23-E33
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Rebhun J, Shin CM, Siddiqui UD, Villa E. Endoscopic biliary treatment of unresectable cholangiocarcinoma: a meta-analysis of survival outcomes and systematic review. World J Gastrointest Endosc 2023; 15 (03) 177-190
    CrossrefPubMedGoogle Scholar
  • 11 Balducci D, Montori M, Martini F. et al. The impact of radiofrequency ablation on survival outcomes and stent patency in patients with unresectable cholangiocarcinoma: a systematic review and meta-analysis of randomized controlled trials. Cancers (Basel) 2024; 16 (07) 1372
    CrossrefPubMedGoogle Scholar
  • 12 Mohan BP, Chandan S, Khan SR. et al. Photodynamic therapy (PDT), radiofrequency ablation (RFA) with biliary stents in palliative treatment of unresectable extrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J Clin Gastroenterol 2022; 56 (02) e153-e160
    CrossrefPubMedGoogle Scholar
  • 13 Chen P, Yang T, Shi P, Shen J, Feng Q, Su J. Benefits and safety of photodynamic therapy in patients with hilar cholangiocarcinoma: a meta-analysis. Photodiagn Photodyn Ther 2022; 37: 102712
    CrossrefPubMedGoogle Scholar
  • 14 Steel AW, Postgate AJ, Khorsandi S. et al. Endoscopically applied radiofrequency ablation appears to be safe in the treatment of malignant biliary obstruction. Gastrointest Endosc 2011; 73 (01) 149-153
    CrossrefPubMedGoogle Scholar
  • 15 Patel J, Rizk N, Kahaleh M. Role of photodynamic therapy and intraductal radiofrequency ablation in cholangiocarcinoma. Best Pract Res Clin Gastroenterol 2015; 29 (02) 309-318
    CrossrefPubMedGoogle Scholar
  • 16 Jarosova J, Macinga P, Krupickova L. et al. Impact of endoluminal radiofrequency ablation on immunity in pancreatic cancer and cholangiocarcinoma. Biomedicines 2022; 10 (06) 1331
    CrossrefPubMedGoogle Scholar
  • 17 Gonzalez-Carmona MA, Möhring C, Mahn R. et al. Impact of regular additional endobiliary radiofrequency ablation on survival of patients with advanced extrahepatic cholangiocarcinoma under systemic chemotherapy. Sci Rep 2022; 12 (01) 1011
    CrossrefPubMedGoogle Scholar
  • 18 Oh DY, Ruth He A, Qin S. et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 2022; 1 (08) a2200015
    PubMedGoogle Scholar
  • 19 Sofi AA, Khan MA, Das A. et al. Radiofrequency ablation combined with biliary stent placement versus stent placement alone for malignant biliary strictures: a systematic review and meta-analysis. Gastrointest Endosc 2018; 87 (04) 944-951.e1
    CrossrefPubMedGoogle Scholar
  • 20 Bokemeyer A, Matern P, Bettenworth D. et al. Endoscopic radiofrequency ablation prolongs survival of patients with unresectable hilar cholangiocellular carcinoma - a case-control study. Sci Rep 2019; 9 (01) 13685
    CrossrefPubMedGoogle Scholar
  • 21 Ross CD, Buerlein DSS, Dushant S. et al. Endobiliary ablation improves survival in patients with unresectable perihilar cholangiocarcinoma compared to stenting alone. Tech Innov Gastrointest Endosc 2022; 24 (03) 226-233
    CrossrefPubMedGoogle Scholar
  • 22 Yang J, Wang J, Zhou H. et al. Efficacy and safety of endoscopic radiofrequency ablation for unresectable extrahepatic cholangiocarcinoma: a randomized trial. Endoscopy 2018; 50 (08) 751-760
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Oh D, Chong J, Song TJ. et al. The usefulness of endobiliary radiofrequency ablation before metal stent placement in unresectable malignant hilar obstruction. J Gastroenterol Hepatol 2022; 37 (11) 2083-2090
    CrossrefPubMedGoogle Scholar
  • 24 Uppal DS, Wang AY. Advances in endoscopic retrograde cholangiopancreatography for the treatment of cholangiocarcinoma. World J Gastrointest Endosc 2015; 7 (07) 675-687
    CrossrefPubMedGoogle Scholar
  • 25 Strand DS, Cosgrove ND, Patrie JT. et al. ERCP-directed radiofrequency ablation and photodynamic therapy are associated with comparable survival in the treatment of unresectable cholangiocarcinoma. Gastrointest Endosc 2014; 80 (05) 794-804
    CrossrefPubMedGoogle Scholar
  • 26 Zheng X, Bo ZY, Wan W. et al. Endoscopic radiofrequency ablation may be preferable in the management of malignant biliary obstruction: a systematic review and meta-analysis. J Dig Dis 2016; 17 (11) 716-724
    CrossrefPubMedGoogle Scholar
  • 27 McCaughan Jr JS, Mertens BF, Cho C, Barabash RD, Payton HW. Photodynamic therapy to treat tumors of the extrahepatic biliary ducts. A case report. Arch Surg 1991; 126 (01) 111-113
    CrossrefPubMedGoogle Scholar
  • 28 Skupin-Mrugalska P, Sobotta L, Kucinska M, Murias M, Mielcarek J, Düzgüneş N. Cellular changes, molecular pathways and the immune system following photodynamic treatment. Curr Med Chem 2014; 21 (35) 4059-4073
    CrossrefPubMedGoogle Scholar
  • 29 Henderson BW, Dougherty TJ. How does photodynamic therapy work?. Photochem Photobiol 1992; 55 (01) 145-157
    CrossrefPubMedGoogle Scholar
  • 30 Cheon YK. The role of photodynamic therapy for hilar cholangiocarcinoma. Korean J Intern Med (Korean Assoc Intern Med) 2010; 25 (04) 345-352
    PubMedGoogle Scholar
  • 31 Baskaran R, Lee J, Yang SG. Clinical development of photodynamic agents and therapeutic applications. Biomater Res 2018; 22: 25
    CrossrefPubMedGoogle Scholar
  • 32 Wagner A, Denzer UW, Neureiter D. et al. Temoporfin improves efficacy of photodynamic therapy in advanced biliary tract carcinoma: a multicenter prospective phase II study. Hepatology 2015; 62 (05) 1456-1465
    CrossrefPubMedGoogle Scholar
  • 33 Ortner ME, Caca K, Berr F. et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 2003; 125 (05) 1355-1363
    CrossrefPubMedGoogle Scholar
  • 34 Zoepf T, Jakobs R, Arnold JC, Apel D, Riemann JF. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol 2005; 100 (11) 2426-2430
    CrossrefPubMedGoogle Scholar
  • 35 Lee TY, Cheon YK, Shim CS. Photodynamic therapy in patients with advanced hilar cholangiocarcinoma: percutaneous cholangioscopic versus peroral transpapillary approach. Photomed Laser Surg 2016; 34 (04) 150-156
    CrossrefPubMedGoogle Scholar
  • 36 Lee TY, Cheon YK, Shim CS, Cho YD. Photodynamic therapy prolongs metal stent patency in patients with unresectable hilar cholangiocarcinoma. World J Gastroenterol 2012; 18 (39) 5589-5594
    CrossrefPubMedGoogle Scholar
  • 37 Witzigmann H, Berr F, Ringel U. et al. Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to r1/r2 resection. Ann Surg 2006; 244 (02) 230-239
    CrossrefPubMedGoogle Scholar
  • 38 Kniebühler G, Pongratz T, Betz CS. et al. Photodynamic therapy for cholangiocarcinoma using low dose mTHPC (Foscan(®)). Photodiagn Photodyn Ther 2013; 10 (03) 220-228
    CrossrefPubMedGoogle Scholar
  • 39 Cosgrove ND, Al-Osaimi AM, Sanoff HK. et al. Photodynamic therapy provides local control of cholangiocarcinoma in patients awaiting liver transplantation. Am J Transplant 2014; 14 (02) 466-471
    CrossrefPubMedGoogle Scholar
  • 40 Wang AY, Yachimski PS. Endoscopic management of pancreatobiliary neoplasms. Gastroenterology 2018; 154 (07) 1947-1963
    CrossrefPubMedGoogle Scholar
  • 41 Schmidt A, Bloechinger M, Weber A. et al. Short-term effects and adverse events of endoscopically applied radiofrequency ablation appear to be comparable with photodynamic therapy in hilar cholangiocarcinoma. United European Gastroenterol J 2016; 4 (04) 570-579
    CrossrefPubMedGoogle Scholar
  • 42 Möhring C, Khan O, Zhou T. et al. Comparison between regular additional endobiliary radiofrequency ablation and photodynamic therapy in patients with advanced extrahepatic cholangiocarcinoma under systemic chemotherapy. Front Oncol 2023; 13: 1227036
    CrossrefPubMedGoogle Scholar
  • 43 Benjamin IS, McPherson GA, Blumgart LH. Iridium-192 wire for hilar cholangiocarcinoma. Lancet 1981; 2 (8246) 582-583
    CrossrefPubMedGoogle Scholar
  • 44 Mukewar S, Gupta A, Baron TH. et al. Endoscopically inserted nasobiliary catheters for high dose-rate brachytherapy as part of neoadjuvant therapy for perihilar cholangiocarcinoma. Endoscopy 2015; 47 (10) 878-883
    Article in Thieme ConnectPubMedGoogle Scholar
  • 45 Skowronek J, Zwierzchowski G. Brachytherapy in the treatment of bile duct cancer - a tough challenge. J Contemp Brachytherapy 2017; 9 (02) 187-195
    CrossrefPubMedGoogle Scholar
  • 46 Taggar AS, Mann P, Folkert MR, Aliakbari S, Myrehaug SD, Dawson LA. A systematic review of intraluminal high dose rate brachytherapy in the management of malignant biliary tract obstruction and cholangiocarcinoma. Radiother Oncol 2021; 165: 60-74
    CrossrefPubMedGoogle Scholar
  • 47 Jin-Seok Park SJ, Kim WC, Lee DH. The efficacy of intraluminal brachytherapy as palliative therapy of hilar cholangiocarcinoma. Korean J Pancreas Biliary Tract 2015; 20: 71-77
    CrossrefPubMedGoogle Scholar